Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
LINC01508
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Not available
Cancer name
Ovarian Cancer
Cancer site
qRT-PCR
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Up
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
33(<=55)+38(>55)
Age range and number
Not available
PMID
Description
Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway
Tissue resource
ovarian serous cystadenomas and normal ovarian epithelium tissues from benign tumor patients
human cisplatin-sensitive ovarian cancer cell lines OV2008
human cisplatin-resistant ovarian cancer cell lines C13K
Experiment
71
Institute
the First Affiliated Hospital of Anhui Medical University
Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Country
China
China
Continent
Asia
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.